Ryan Jacobs, MD, discusses real-world data showing that first-line zanubrutinib was associated with longer time to next treatment and improved overall survival vs acalabrutinib in patients with CLL/SLL.
ADVERTISEMENT
ADVERTISEMENT
2026 Copyright © News-Matic.com. All Rights Reserved
